CENTOGENE Announces Partnership with OESIS Network for COVID-19 PCR Testing for US School Populations

CAMBRIDGE, Mass. and SANTA MONICA, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network Inc, an innovation network of more than 600 schools across the U.S., today announced a partnership for COVID-19 screening of schools. The partnership will offer RT-PCR testing that can aid schools in their return to campus in the fall and continued screening to prevent a resurgence of COVID-19 over the course of the academic school year.

The partnership addresses the unique challenges facing schools in the following ways:

  • Given the precious resources of schools public and private, the test will be offered at an affordable price and less than the COVID-19 clinical diagnostic reimbursement price announced in April for Medicare Part B for high throughput, technician intensive, and time intensive tests. The partnership is also investigating the possibility of offering pooled pricing for schools that perform regular testing, once an initial baseline has been established. This approach could incorporate pooled testing, where test samples are batched - potentially reducing analytical costs.
  • Given the need to test both students and employees, the sample collection will use CentoSwab™, CENTOGENE’s validated, CE-labeled, ethylene oxide-treated swabs and collection tubes that can ship directly to school sampling locations. This FDA listed, class 1 medical device is an oropharyngeal swab and does not require a medical expert, a stabilization buffer, or specialized kits.
  • Given the need for accuracy, the testing will use RT-PCR and will be conducted at a CENTOGENE lab, certified by the College of American Pathologists and as a CLIA lab, authorized to do moderate to complex diagnostics required for PCR testing.
  • Given the time-pressure around the beginning of the school year in August and September, up to 50,000 tests per week are available for this partnership at this time and can be increased upon demand. All logistics for sample collection will be handled by CENTOGENE and its logistics partners to ensure sample collection, delivery, and analysis in a timely manner.
  • Given the importance of ensuring the highest levels of privacy and data protection, the schools will not be providing identifying information to CENTOGENE or OESIS on who the samples came from, rather a simple numerical identifier on the swab container that will be accessed by the school using a digital web portal. It will be the responsibility of the schools to inform those who would have tested positive, as well as other required disclosures to local health authorities.

Sanje Ratnavale, President of OESIS Network, stated, “CENTOGENE has all the operational attributes we were looking for including reputation, quality, capacity, logistics and price. We were drawn to its experience and credentials testing high school students and teachers already for COVID-19, who provided us with the necessary references. Although many of the schools in our network are independent, this program will be equally available to public and Title 1 schools, particularly if they are able to access Cares Act funding potentially for such uses.”

Dr. Jennifer Zaccara, Head of School at the Vermont Academy in Saxtons River, Vermont, commented on the announcement, “OESIS simply ‘went to bat’ for schools when they needed support. As a result, we now have access to COVID-19 testing at affordable rates.”

Robert de Deugd, Senior Vice President of Global Sales at CENTOGENE, said, “To overcome this global pandemic, it is vital that we work together to create worldwide solutions – preventing a further outbreak and enabling students to continue to focus with their educational journey. Working alongside the OESIS Network Inc, we will be able to provide highly validated, precise testing to schools throughout the U.S. We are very enthusiastic that this initiative will enable students and staff to return to the classroom, while continuously keeping their health, safety, and peace of mind at the forefront.”

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.

OESIS is an innovation network of 600 mostly independent K-12 schools across the United States. Its mission is to catalyze change in the learning models of schools with an emphasis on the innovative practices in pedagogy, curriculum development, 21st-century assessment and school culture change. Through its research, its professional development platforms, its student e-portfolios, its national publications, and its conferences, it covers all areas of student-centered learning including Project-Based Learning, Mastery, 21st Century Assessment, STEAM, Experiential Learning, Global Collaboration, Blended Learning, Inquiry Driven Models and more.

Important Notice and Disclaimer

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CENTOGENE Contact: Ben Legg Corporate Communications press@centogene.com Media Contact: FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com OESIS Contact: www.oesisgroup.com media@oesisgroup.com

Primary Logo

Back to news